Efficacy of CD40 ligand gene therapy in malignant mesothelioma

Paul L. Friedlander, Christie L. Delaune, Jennifer M. Abadie, Marisa Toups, Jeffrey LaCour, Luis Marrero, Qiu Zhong, Jay K. Kolls

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Gene delivery of CD40 Ligand (CD40L) has shown promise in murine models of melanoma and adenocarcinoma; however, its potential for thoracic malignancies such as malignant mesothelioma remains unclear. In this study, we investigated the hypothesis that CD40L gene therapy would be effective in local and distant tumor suppression in mesothelioma using an immunocompetent murine model. Using a recombinant adenovirus encoding murine CD40L (AdCD40L), we demonstrated no suppression of in vitro cell growth for the AC29 (mesothelioma) cell line. However, inoculation of immunocompetent CBA/J mice with AC29 cells treated ex vivo with AdCD40L resulted in significant suppression of tumor formation in vivo when compared with controls (P < 0.001). Intratumoral inoculation of AdCD40L into previously established AC29 tumors yielded similar antitumor results and was associated with increased recruitment of intratumoral CD8 + T cells. Adoptive transfer of CD8+ T cells from AdCD40L-treated tumor bearing mice conferred protection to naive mice given an AC29 tumor challenge. Finally, in mice with two synchronous tumors, treatment of one of the tumors with AdCD40L resulted in a regression of both tumors. These findings demonstrate the development of tumor specific CD8+ T cells by AdCD40L and support the further development of AdCD40L for the treatment of malignant mesothelioma.

Original languageEnglish (US)
Pages (from-to)321-330
Number of pages10
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume29
Issue number3 I
DOIs
StatePublished - Sep 1 2003

Fingerprint

Gene therapy
CD40 Ligand
Genetic Therapy
Tumors
Adenoviridae
Neoplasms
T-cells
Mesothelioma
T-Lymphocytes
Bearings (structural)
Malignant Mesothelioma
Inbred CBA Mouse
Cell growth
Adoptive Transfer
Genes
Melanoma
Cells
Adenocarcinoma
Thorax
Cell Line

ASJC Scopus subject areas

  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Clinical Biochemistry
  • Cell Biology

Cite this

Friedlander, P. L., Delaune, C. L., Abadie, J. M., Toups, M., LaCour, J., Marrero, L., ... Kolls, J. K. (2003). Efficacy of CD40 ligand gene therapy in malignant mesothelioma. American Journal of Respiratory Cell and Molecular Biology, 29(3 I), 321-330. https://doi.org/10.1165/rcmb.2002-0226OC

Efficacy of CD40 ligand gene therapy in malignant mesothelioma. / Friedlander, Paul L.; Delaune, Christie L.; Abadie, Jennifer M.; Toups, Marisa; LaCour, Jeffrey; Marrero, Luis; Zhong, Qiu; Kolls, Jay K.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 29, No. 3 I, 01.09.2003, p. 321-330.

Research output: Contribution to journalArticle

Friedlander, PL, Delaune, CL, Abadie, JM, Toups, M, LaCour, J, Marrero, L, Zhong, Q & Kolls, JK 2003, 'Efficacy of CD40 ligand gene therapy in malignant mesothelioma', American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 3 I, pp. 321-330. https://doi.org/10.1165/rcmb.2002-0226OC
Friedlander, Paul L. ; Delaune, Christie L. ; Abadie, Jennifer M. ; Toups, Marisa ; LaCour, Jeffrey ; Marrero, Luis ; Zhong, Qiu ; Kolls, Jay K. / Efficacy of CD40 ligand gene therapy in malignant mesothelioma. In: American Journal of Respiratory Cell and Molecular Biology. 2003 ; Vol. 29, No. 3 I. pp. 321-330.
@article{7132816507a544a79d73868a46305f02,
title = "Efficacy of CD40 ligand gene therapy in malignant mesothelioma",
abstract = "Gene delivery of CD40 Ligand (CD40L) has shown promise in murine models of melanoma and adenocarcinoma; however, its potential for thoracic malignancies such as malignant mesothelioma remains unclear. In this study, we investigated the hypothesis that CD40L gene therapy would be effective in local and distant tumor suppression in mesothelioma using an immunocompetent murine model. Using a recombinant adenovirus encoding murine CD40L (AdCD40L), we demonstrated no suppression of in vitro cell growth for the AC29 (mesothelioma) cell line. However, inoculation of immunocompetent CBA/J mice with AC29 cells treated ex vivo with AdCD40L resulted in significant suppression of tumor formation in vivo when compared with controls (P < 0.001). Intratumoral inoculation of AdCD40L into previously established AC29 tumors yielded similar antitumor results and was associated with increased recruitment of intratumoral CD8 + T cells. Adoptive transfer of CD8+ T cells from AdCD40L-treated tumor bearing mice conferred protection to naive mice given an AC29 tumor challenge. Finally, in mice with two synchronous tumors, treatment of one of the tumors with AdCD40L resulted in a regression of both tumors. These findings demonstrate the development of tumor specific CD8+ T cells by AdCD40L and support the further development of AdCD40L for the treatment of malignant mesothelioma.",
author = "Friedlander, {Paul L.} and Delaune, {Christie L.} and Abadie, {Jennifer M.} and Marisa Toups and Jeffrey LaCour and Luis Marrero and Qiu Zhong and Kolls, {Jay K.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1165/rcmb.2002-0226OC",
language = "English (US)",
volume = "29",
pages = "321--330",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "3 I",

}

TY - JOUR

T1 - Efficacy of CD40 ligand gene therapy in malignant mesothelioma

AU - Friedlander, Paul L.

AU - Delaune, Christie L.

AU - Abadie, Jennifer M.

AU - Toups, Marisa

AU - LaCour, Jeffrey

AU - Marrero, Luis

AU - Zhong, Qiu

AU - Kolls, Jay K.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Gene delivery of CD40 Ligand (CD40L) has shown promise in murine models of melanoma and adenocarcinoma; however, its potential for thoracic malignancies such as malignant mesothelioma remains unclear. In this study, we investigated the hypothesis that CD40L gene therapy would be effective in local and distant tumor suppression in mesothelioma using an immunocompetent murine model. Using a recombinant adenovirus encoding murine CD40L (AdCD40L), we demonstrated no suppression of in vitro cell growth for the AC29 (mesothelioma) cell line. However, inoculation of immunocompetent CBA/J mice with AC29 cells treated ex vivo with AdCD40L resulted in significant suppression of tumor formation in vivo when compared with controls (P < 0.001). Intratumoral inoculation of AdCD40L into previously established AC29 tumors yielded similar antitumor results and was associated with increased recruitment of intratumoral CD8 + T cells. Adoptive transfer of CD8+ T cells from AdCD40L-treated tumor bearing mice conferred protection to naive mice given an AC29 tumor challenge. Finally, in mice with two synchronous tumors, treatment of one of the tumors with AdCD40L resulted in a regression of both tumors. These findings demonstrate the development of tumor specific CD8+ T cells by AdCD40L and support the further development of AdCD40L for the treatment of malignant mesothelioma.

AB - Gene delivery of CD40 Ligand (CD40L) has shown promise in murine models of melanoma and adenocarcinoma; however, its potential for thoracic malignancies such as malignant mesothelioma remains unclear. In this study, we investigated the hypothesis that CD40L gene therapy would be effective in local and distant tumor suppression in mesothelioma using an immunocompetent murine model. Using a recombinant adenovirus encoding murine CD40L (AdCD40L), we demonstrated no suppression of in vitro cell growth for the AC29 (mesothelioma) cell line. However, inoculation of immunocompetent CBA/J mice with AC29 cells treated ex vivo with AdCD40L resulted in significant suppression of tumor formation in vivo when compared with controls (P < 0.001). Intratumoral inoculation of AdCD40L into previously established AC29 tumors yielded similar antitumor results and was associated with increased recruitment of intratumoral CD8 + T cells. Adoptive transfer of CD8+ T cells from AdCD40L-treated tumor bearing mice conferred protection to naive mice given an AC29 tumor challenge. Finally, in mice with two synchronous tumors, treatment of one of the tumors with AdCD40L resulted in a regression of both tumors. These findings demonstrate the development of tumor specific CD8+ T cells by AdCD40L and support the further development of AdCD40L for the treatment of malignant mesothelioma.

UR - http://www.scopus.com/inward/record.url?scp=0041328759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041328759&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2002-0226OC

DO - 10.1165/rcmb.2002-0226OC

M3 - Article

C2 - 12676804

AN - SCOPUS:0041328759

VL - 29

SP - 321

EP - 330

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 3 I

ER -